Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia(UCLA Health), Kevin Kalinsky(Emory University), Alessandro D. Santin(Yale University), William A. Wegener(Children's Hospital of Philadelphia), Ala M. Sweidan(Cornell University), Joyce O’Shaughnessy(Baylor University Medical Center), Robert M. Sharkey(Immunomedics (United States)), Jennifer R. Diamond(University of Colorado Anschutz Medical Campus), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), Sara M. Tolaney(Harvard University), Ingrid A. Mayer(Vanderbilt University), Sarah A. Washkowitz(Cornell University), Vandana G. Abramson(Vanderbilt University), Hope S. Rugo(City of Hope), Robert Iannone(Cornell University), Nikita Shah(Orlando Health), Steven J. Isakoff(Harvard University), Rebecca Moroose(Orlando Health), David M. Goldenberg(Unknown)
Cited by 846
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k